Catalyst Pharmaceuticals, Inc. has announced a settlement agreement with Teva Pharmaceuticals, resolving the patent ...
Cullinan offers promising oncology and autoimmune products, strong financials, and potential for growth, making it a ...
Catalyst Pharmaceuticals settles patent litigation with Teva, delaying generic Firdapse launch until 2035. Legal actions against other defendants remain ongoing.
Zacks.com on MSN21h
CPRX Stock Rises 17% on Settling Firdapse Patent Litigation With TevaShares of Catalyst Pharmaceuticals CPRX gained 16.7% on Wednesday after the company, along with its licensor, SERB, announced ...
Despite weathering significant criticism from lawmakers and patient groups over the steep cost of its rare disease med ...
The global contact and convective dryers market is on a robust trajectory, with Future Market Insights (FMI) projecting a ...
Stephens has recently initiated Catalyst Pharmaceuticals Inc (CPRX) stock to Overweight rating, as announced on November 18, 2024, according to Finviz. Earlier, on March 14, 2024, Citigroup had ...
Some of the best possible returns for investors come by not going after megacaps, but instead pursuing stocks that have more ...
Citi analyst Samantha Semenkow has maintained their bullish stance on CPRX stock, giving a Buy rating today.Stay Ahead of the Market:Discover ...
The stock's rise snapped a three-day losing streak.
Catalyst struck a deal Wednesday with Teva that will prevent the generic drugmaker from knocking off Firdapse until 2035.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback